Get the Stockscreener App
395.47
9.07%
-41.76
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $395.47, with a volume of 3.73M.
It is down -9.07% in the last 24 hours and down -3.25% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$437.23
Open:
$408.9
24h Volume:
3.73M
Relative Volume:
1.42
Market Cap:
$213.91B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
27.50
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
-9.25%
1M Performance:
-3.25%
6M Performance:
+7.59%
1Y Performance:
+41.90%
1-Day Range:
$392.00
$410.02
1-Week Range:
$392.00
$445.81
52-Week Range:
$269.77
$447.03
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
395.67 | 236.38B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,126.36 | 1.02T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
270.76 | 663.28B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
250.62 | 453.19B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
148.52 | 370.89B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
137.82 | 304.10B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen: Why Rivals' Cholesterol Drug Fail Is Bad News For The Pharma (Rating Downgrade) - Seeking Alpha
Amgen Stock Eyes Worst Day Since 2000 on Novartis Lp(a) FailureAmgen (NASDAQ:AMGN) - Benzinga
S&P 500, Nasdaq Slip as $98 Brent Reignites Inflation Fears: Stock Market Today - Benzinga
Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14% - Yahoo Finance
Amgen, Salesforce Share Losses Contribute To Dow's 525-Point Fall - Moomoo
What's Going On With Amgen Stock Tuesday? - Benzinga
Amgen, Novartis, Qualcomn, Corning, Lumentum, and More Stocks That Explain Today’s Market - barrons.com
Amgen caught in the crossfire of Novartis' failure - marketscreener.com
Amgen (NASDAQ:AMGN) Shares Gap DownHere's Why - marketbeat.com
Amgen (NASDAQ:AMGN): What’s Driving the Fresh Market Buzz? - Kalkine Media
Disappointing Clinical Trial Results Are Dragging Novartis, Amgen and the Dow Lower Tuesday - Yahoo Finance
AstraZeneca and Amgen clear a milestone in small cell lung cancer - marketscreener.com
Why Amgen Stock Is Down 8.7% And What's Next After Lp(a) Drug Doubts - simplywall.st
Amgen drops on Novartis trial setback for heart therapy; BMO downgrades - Seeking Alpha
Amgen Announces Landmark Results From The Phase 3 DeLLphi-305 Study Demonstrating Statistically Significant And Clinically Meaningful Improvement In Overall Survival With IMDELLTRA In Combination With Imfinzi Compared To Durvalumab Alone - marketscreener.com
Amgen Inc Stock (AMGN) Moved Down by 8.33% on Sep 8: A Full Analysis - TradingKey
Why Amgen Stock Is Getting Hit by a Novartis Trial Setback - barrons.com
AMGN Reiterated by Cantor Fitzgerald -- Price Target Maintained at $400 - GuruFocus
This Best Buy Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday - Benzinga
Novartis pelacarsen Lp(a) trial fails, raising doubts for Amgen, Lilly - qz.com
Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus - Zacks Investment Research
Amgen (NASDAQ:AMGN) Receives "Neutral" Rating from Cantor Fitzgerald - marketbeat.com
Is AMGN Overvalued? DCF Says Worth $296 - GuruFocus
BMO lowers Amgen, BioNTech to Market Perform as risk-reward shifts - Investing.com Canada
Amgen Shares Fall as Investors Assess Novartis Lp(a) Trial Result and BMO Downgrade - Yahoo Finance
Novartis Faces Setback with Pelacarsen Clinical Trial, Impacting Competitors - GuruFocus
Why Amgen Stock Is Dropping After Swiss Rival’s Trial Setback - Barron's
Why is Amgen stock sliding today? By Investing.com - Investing.com Canada
BMO Capital Downgrades Amgen to Market Perform From Outperform, Price Target is $450 - marketscreener.com
VIRGINIA RETIREMENT SYSTEMS ET Al Purchases Shares of 80,985 Amgen Inc. $AMGN - marketbeat.com
Analyst recommendations: Amgen, Equifax, Lockheed Martin, Phillips 66, Valero Energy… - marketscreener.com
Understanding Momentum Shifts in (AMGN) - news.stocktradersdaily.com
Ameritas Advisory Services LLC Has $5.11 Million Stake in Amgen Inc. $AMGN - marketbeat.com
Rep. David Taylor Sells Off Amgen Inc. (NASDAQ:AMGN) Stock - marketbeat.com
Amgen stock heads into the open after a 1.55% pullback - AD HOC NEWS
Amgen Seeks Korean Partners in AI Drug Discovery, Obesity - Seoul Economic Daily
Amgen's 7,297-Patient Heart Bet Just Inherited a Higher Bar - TradingView
Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal - Yahoo Finance
Amgen stock holds near 52-week high as major investors adjust positions - AD HOC NEWS
HighTower Advisors LLC Sells 4,063 Shares of Amgen Inc. $AMGN - marketbeat.com
Analyst recommendations: Amgen, Broadcom, Lululemon, Palo Alto Networks… - marketscreener.com
Amgen Inc. (AMGN) Stock Analysis: Evaluating the Dividend Potential and Analyst Ratings in a Competitive Market - DirectorsTalk Interviews
Why Could Tuesday Reopening Put Amgen (NASDAQ:AMGN) in Focus? - Kalkine Media
California State Teachers Retirement System Buys 297,430,677 Shares of Amgen Inc. $AMGN - marketbeat.com
Amundi Purchases 512,883 Shares of Amgen Inc. $AMGN - marketbeat.com
Amgen Inc. $AMGN Stake Boosted by Saudi Central Bank - marketbeat.com
Nilsine Partners LLC Makes New Investment in Amgen Inc. $AMGN - marketbeat.com
MW Advisory LLC Makes New $1.05 Million Investment in Amgen Inc. $AMGN - marketbeat.com
TD Waterhouse Canada Inc. Sells 18,281 Shares of Amgen Inc. $AMGN - marketbeat.com
Amgen (NASDAQ:AMGN) Shares Sold Off Sen. Sheldon Whitehouse - MarketBeat
Should TEZSPIRE’s EoE Win and Cardiometabolic Data Shift Amgen’s (AMGN) Immunology Narrative? - simplywall.st
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amgen Inc Stock (AMGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Khosla Rachna | SVP, Business Development |
Aug 11 '26 |
Sale |
412.57 |
2,000 |
825,134 |
6,404 |
| Khosla Rachna | SVP, Business Development |
Aug 13 '26 |
Sale |
416.43 |
1,252 |
521,365 |
6,404 |
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):